Risk Reducing Salpingectomy with Delayed Oophorectomy as an

Recruiting

99 years and younger

Female

Phase N/A

1 Location

Brief description of study

The purpose of the study is to compare risk reducing salpingectomy with delayed oophorectomy to risk-reducing salpingo-oophorectomy in high risk-women.

Detailed description of study

To enroll, patients must meet eligibility criteria and sign ICF (no additional testing needed). After enrolling, patients fill out demographic and family history questionnaires. After surgery (RRSO or RRS/RRO), patients will have yearly follow-ups so the study team can collect information about the patient's health status.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Ovarian cancer prevention. BRCA1, BRCA2, BRIP1, RAD51C, RAD51D
Age: - 99 Years
Gender: Female

Inclusion

1. Premenopausal women with a documented deleterious mutation in BRCA1, BRCA2, BRIP1, RAD51C and/or RAD51D gene germline mutation

2. Age 25-40 years for BRCA1 mutation carriers, 25-45 years for BRCA2 and 30-50 years for BRIP1, RAD51C, RAD51D

3. Childbearing completed or no longer requires fallopian tubes

4. Presence of at least one fallopian tube

5. Participants may have a personal history of non-ovarian malignancy

6. Informed consent must be obtained and documented

Exclusion

1. Post menopausal status (natural menopause or due to (cancer) treatment)

2. Wish for second stage RRO within two years after RRS (if clear at enrollment)

3. Legally incapable

4. Prior bilateral salpingectomy

5. A personal history of ovarian, fallopian tube or peritoneal cancer

6. Current clinical signs, diagnosis or treatment for malignant disease

Updated on 01 Aug 2024. Study ID: 855818

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).